672 completed, 114 active not recruiting, 92 recruiting, 61 terminated. 976 Phase 3, 45 Phase 2.
By phase and status
Phase Trials Status Phase 3 976 Completed 672 , Active not recruiting 114 , Recruiting 92 , Terminated 61 , Unknown 13 , Withdrawn 13 , Not yet recruiting 8 , Enrolling by invitation 2 , Suspended 1 Phase 2 45 Completed 35 , Recruiting 4 , Terminated 4 , Active not recruiting 1 , Unknown 1
Follow AstraZeneca: new trials by email
Trials (filtered) newest first · largest first
All 976 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes AZD6234, Placebo - Obesity, Overweight Phase 3 Not yet recruiting 330 2027-01-04 2026-11-06 A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma Phase 3 Not yet recruiting 1200 2026-12-22 2026-11-02 Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing NSAI + CDK4/6i, NSAI + CDK4/6i + Capivasertib, Fulvestrant + CDK4/6i + Capivasertib - HR Positive/HER-2 Negative Breast Cancer Phase 3 Not yet recruiting 1084 2026-10-30 2026-09-03 A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. FLOT Chemotherapy, Durvalumab - Gastric, Esophagogastric Junction Phase 3 Recruiting 140 2026-10-09 2026-11-06 Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer. Tumor assessment, Completion of Quality-of-life questionnaires, ECG - Metastatic Invasive Breast Cancer Phase 3 Not yet recruiting 370 2026-09-25 2026-07-21 Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer Phase 3 Recruiting 600 2026-09-24 2026-10-16 A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). AZD0120, Cyclophosphamide, Fludarabine - Newly Diagnosed Multiple Myeloma (NDMM) Phase 3 Recruiting 750 2026-09-24 2026-10-21 T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer Phase 3 Recruiting 200 2026-09-18 2026-10-16 A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension. baxdrostat 2mg, Placebo 2mg - Uncontrolled Hypertension Phase 3 Recruiting 286 2026-09-17 2026-10-15 Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer Phase 3 Recruiting 950 2026-09-16 2026-11-06 Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) Saruparib, Placebo, Enzalutamide - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase 3 Recruiting 1330 2026-09-15 2026-10-15 A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3 - Hypercholesterolaemia Phase 3 Recruiting 200 2026-09-10 2026-10-05 A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin - Renal Insufficiency, Chronic Phase 3 Recruiting 2800 2026-09-01 2026-09-24 A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus Anifrolumab - Lupus Erythematosus, Systemic Phase 3 Recruiting 417 2026-08-31 2026-10-22 Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment Anifrolumab - Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus Phase 3 Recruiting 1072 2026-08-31 2026-10-28 A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF Elecoglipron, Placebo - Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) Phase 3 Recruiting 6950 2026-08-24 2026-09-28 A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus Lenbelintide, Placebo - Obesity or Overweight, Weight-Related Comorbidity Phase 3 Recruiting 500 2026-08-24 2026-11-09 A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. Elecoglipron, Placebo - Chronic Kidney Disease Phase 3 Recruiting 7000 2026-08-21 2026-09-09 A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus Elecoglipron, Placebo - Obesity, Overweight Phase 3 Recruiting 351 2026-08-21 2026-11-09 A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight Lenbelintide, Placebo - Obesity or Overweight, Diabetes Mellitus, Type 2 Phase 3 Recruiting 1500 2026-08-20 2026-10-28
Showing 20 of 976. Sign in to see all of them.
Conditions studied Diabetes Mellitus, Type 2 (127) · Asthma (123) · Breast Neoplasms (65) · Pulmonary Disease, Chronic Obstructive (59) · Diabetes Mellitus (52) · Carcinoma, Non-Small-Cell Lung (46) · Hypercholesterolemia (24) · Neoplasm Metastasis (23) · Schizophrenia (23) · Bipolar Disorder (20) · Prostatic Neoplasms (20) · Hypertension (19) · Lung Diseases (18) · Respiratory Tract Diseases (17) · Depression (16)
Interventions dapagliflozin (65) · durvalumab (64) · Quetiapine Fumarate (53) · Budesonide (52) · Rosuvastatin Calcium (45) · Budesonide, Formoterol Fumarate Drug Combination (44) · Carboplatin (43) · Cisplatin (40) · Esomeprazole (39) · Exenatide (39) · Metformin (35) · benralizumab (35) · saxagliptin (35) · Formoterol Fumarate (30) · ciclesonide (29)
Countries United States (536) · Canada (365) · Germany (349) · Spain (311) · Poland (310) · United Kingdom (293) · France (282) · Italy (276) · South Korea (271) · Japan (266) · China (241) · Brazil (228) · Australia (227) · Hungary (227) · Taiwan (225)
Top investigators Catherine Bonuccelli (11) · Esther Garcia, MD (11) · Russell Esterline (11) · James Malone, MD (8) · Lisa Porter, MD (7) · Deborah Price, MSc (6)
Results publications PMID 38770818 , PMID 22236356 , PMID 22913891 , PMID 26894924 , PMID 27402391 , PMID 24816198 , PMID 32306296 , PMID 40311309 , PMID 23748506 , PMID 24067192 , PMID 24175720 , PMID 26474010 , PMID 27033025 , PMID 27160944 , PMID 36005278 , PMID 42551404 , PMID 20102307 , PMID 23485955 , PMID 23497790 , PMID 23795975 , PMID 28419462 , PMID 29536781 , PMID 33368935 , PMID 34473343 , PMID 35713300 , PMID 36472162 , PMID 38682786 , PMID 40913594 , PMID 42476723 , PMID 19196892 , PMID 19451554 , PMID 21225239 , PMID 21309844 , PMID 21680990 , PMID 22129214 , PMID 22143997 , PMID 22304793 , PMID 22329608 , PMID 23522121 , PMID 23673347 , PMID 24394383 , PMID 25326006 , PMID 25414932 , PMID 25670896 , PMID 26498386 , PMID 26612545 , PMID 27342744 , PMID 27461213 , PMID 28074135 , PMID 29331313
NIH funding 2023 (64) , 2018 (25) , 2019 (21) , 2025 (21) , 2014 (15) , 2015 (10) , 2016 (9) , 2017 (9) , 2005 (5) , 2004 (2) , 2009 (2) , 2008 (1) , P30CA016672 (1) , U01NS117450 (1) , U10CA180868 (1)